Clinigen and Shionogi CEOs meet for signing ceremony to reaffirm new strategic relationship and reinforce commitment to accelerating ethical patient access to antibiotic addressing antimicrobial resistance in Australia and New Zealand

LONDON, UK, 29 May 2025: Clinigen, the global specialty pharmaceutical services group, today highlights a key collaborative milestone with Shionogi, an impact-driven pharmaceutical company, marking the launch of their new strategic relationship. Clinigen CEO Jerome Charton met last week with Shionogi President and CEO Dr Isao Teshirogi at the Shionogi global headquarters in Osaka, Japan, for a ceremonial signing event to mark the progress following the exclusive licensing agreement for cefiderocol announced by Shionogi in April. 

The agreement grants Clinigen's Australian subsidiary, Link Medical Products Pty Ltd, the exclusive rights for the development and commercialisation of cefiderocol in Australia and New Zealand. Cefiderocol is not yet approved for use in Australia and New Zealand. The Therapeutic Goods Administration (TGA) regulatory authority in Australia accepted the market authorisation application for cefiderocol in December 2024 and the application is under evaluation¹.  

Under the terms of the agreement, Clinigen will in-license cefiderocol from Shionogi and obtain exclusive rights for its development and commercialisation in Australia and New Zealand. Shionogi will receive an upfront payment, milestone payments based on development progress, and royalties from Clinigen. 

The signing ceremony celebrated this new strategic relationship between the two companies and their shared commitment to expanding potential access to cefiderocol in Australia and New Zealand.  

Jerome Charton, CEO of Clinigen, says: “Establishing a new strategic relationship with a respected innovator in impactful medicines like Shionogi is a pivotal moment for Clinigen. Our work together to potentially bring cefiderocol to Australia and New Zealand in the future enables us to support the broader response to growing antimicrobial resistance, while simultaneously building a valuable presence in the growing Asia Pacific market.” 

Dr Isao Teshirogi, Shionogi President and CEO, comments: “Shionogi is committed to the research and development of innovative treatments for infectious diseases for the benefit of patients around the world, addressing urgent global health challenges such as antimicrobial resistance. We are pleased to initiate this new collaboration with Clinigen for cefiderocol in Australia and New Zealand to expand the access to cefiderocol for patients who can benefit from it. Clinigen’s established market presence makes them an ideal partner.” 

This press release contains information about medicines that may not be approved in all territories. The intent of this press release is to share pertinent information with the investment community about this collaboration between Clinigen and Shionogi and does not constitute promotion of any medicines.